Manufacturer
Sanofi-Aventis Deutschland GmbH
Contents
Insulin glargine
Indication
DM where treatment w/ insulin is required in adult, adolescent & childn ≥2 yr.
Instruction
Administer via SC injection once daily at the same time everyday. Dose & timing should be individually adjusted
Drug interaction
May increase blood glucose lowering effect & susceptibility to hypoglycemia w/ oral antidiabetic products, ACE inhibitors, salicylates, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, sulfonamides. May reduce blood lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, sympathomimetic agents (eg, epinephrine, salbutamol, terbutaline), glucagon, INH, phenothiazine derivates, somatropin, thyroid hormones, estrogens, progestogens (eg, OCs), PIs & atypical antipsychotic medications (eg, olanzapine & clozapine). Potentiated or weakened blood glucose lowering effect w/ β-blockers, clonidine, lithium salts & alcohol. Pentamidine may cause hypoglycemia, (sometimes) followed by hyperglycemia. Reduced or no signs of adrenergic counter regulation w/ β-blockers, clonidine, guanethidine & reserpine.
Malaysia
